Management of Fatigue and Mental Fog in Patient on Apixaban
The next step is to evaluate whether these symptoms are truly related to apixaban by checking renal function, reviewing the dose appropriateness, assessing for drug interactions, and considering a trial switch to an alternative anticoagulant if symptoms persist after ruling out other causes.
Initial Assessment
Before attributing symptoms to apixaban, several key factors must be evaluated:
Verify appropriate dosing: The standard dose is 5 mg twice daily, but should be reduced to 2.5 mg twice daily if the patient has ≥2 of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1.
Check renal function: Apixaban has 25% renal excretion, and accumulation can occur with declining kidney function 2. Renal function should be monitored during any intercurrent illness or medication changes 2. Elevated apixaban levels have been documented in elderly patients with chronic kidney disease, with concentrations persisting longer than expected 3, 4.
Review concomitant medications: Combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) can increase apixaban levels and may require dose reduction 1.
Rule out other causes: Fatigue and cognitive symptoms can result from multiple conditions common in anticoagulated patients, including anemia from occult bleeding, thyroid dysfunction, or other comorbidities.
Evidence for Neurological Side Effects
While uncommon, reversible neurological adverse reactions to apixaban have been documented:
A case report described an 80-year-old woman who developed imbalance, non-vertiginous dizziness, headache, confusion/disorientation, and asthenia within days of starting apixaban 5. Her apixaban plasma concentration was 4 times higher than the laboratory upper limit of normal 5.
Symptoms resolved within 72 hours of discontinuation and did not recur when switched to rivaroxaban 5.
Advanced age and chronic renal failure may predispose patients to these effects 5.
Management Algorithm
Step 1: Laboratory Evaluation
- Obtain complete blood count (to assess for anemia from bleeding)
- Check renal function (creatinine, estimated CrCl)
- Consider apixaban-calibrated anti-Xa level if available, particularly in elderly patients or those with renal insufficiency 3
Step 2: Dose Verification
- If patient meets criteria for dose reduction (≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) but is receiving 5 mg twice daily, reduce to 2.5 mg twice daily 1
- If already on appropriate dose and symptoms persist, proceed to Step 3
Step 3: Consider Alternative Anticoagulation
If symptoms persist after ruling out other causes and optimizing dose:
Switch to rivaroxaban as the primary alternative:
- Rivaroxaban 20 mg once daily (or 15 mg once daily if CrCl 15-50 mL/min) 6
- Evidence suggests rivaroxaban may be better tolerated in some patients who experience neurological symptoms with apixaban 5
- However, rivaroxaban has higher bleeding rates than apixaban in head-to-head comparison 7, 8
Alternative options if rivaroxaban is not suitable:
- Dabigatran 150 mg twice daily (consider 110 mg twice daily if age >75 years or increased bleeding risk) 2
- Edoxaban 60 mg once daily (30 mg if CrCl 30-50 mL/min or weight <60 kg) 6
- Return to warfarin if DOACs are not tolerated, though this requires INR monitoring 9, 10
Important Caveats
Apixaban generally has favorable safety profile: In the ARISTOTLE trial, apixaban was associated with less major bleeding and lower mortality compared to warfarin 10, 11, and recent data show lower bleeding risk than rivaroxaban 7.
Switching considerations: When switching from apixaban to another anticoagulant, discontinue apixaban and begin the new anticoagulant at the time of the next scheduled apixaban dose 1.
Document the trial: If switching anticoagulants, clearly document the temporal relationship between symptoms and medication to establish causality.
Monitor after switch: Symptoms should resolve within 72 hours if truly apixaban-related 5. If symptoms persist with alternative anticoagulation, investigate other etiologies more thoroughly.